Mendel Goldfinger

9PUBLICATIONS
48CO-AUTHORS
Respiratory diseasesHaematological tumoursGene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 06, 2026
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

Lemchukwu Amaeshi, Lauren Laufer, Kateryna Fedorov

|Sep 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri

|Jun 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.

David Levitz, Yogen Saunthararajah, Kateryna Fedorov

|Oct 18, 2022
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub

|Sep 23, 2021
Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.

Phaedon D Zavras, Aditi Shastri, Mendel Goldfinger

|May 03, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.

Vikas Mehta, Sanjay Goel, Rafi Kabarriti

Pageof 2

Frequent Collaborators

5 joint publications

Kira Gritsman

4 joint publications

R Alejandro Sica

4 joint publications

Lauren C Shapiro

4 joint publications

Nishi Shah